Suzette Delaloge

Université Paris-Saclay — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

88h-index36.1kcitations822works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(236), Advanced Breast Cancer Therapies(176), HER2/EGFR in Cancer Research(140), Cancer Treatment and Pharmacology(139), Cancer Genomics and Diagnostics(98)

Publications818 total

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial
UNC Libraries·2025Open Access
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort
European Journal of Cancer·2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
Annals of Oncology·2025· 1 cited
ESMO basic requirements for AI-based biomarkers in oncology (EBAI)
Annals of Oncology·2025· 7 citedOpen Access
Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Supplementary Appendix 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Supplementary Appendix 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Protocol 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Data from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Figure S2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Supplemental Table 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Figure S1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Supplemental Table 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Supplemental Table 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
2025Open Access
Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study)
European Journal of Cancer·2025· 1 cited
Evaluating breast cancer screening consortium and MammoRisk plus polygenic risk score 313 for breast cancer risk prediction in UK Biobank
European Journal of Cancer·2025
Évolutions souhaitables du dépistage organisé du cancer du sein en France : préconisations de la Société d’imagerie de la femme et de la Société française de sénologie et de pathologie mammaire
Imagerie de la Femme·2025Open Access
La vision des cliniciens sur le dépistage du cancer du sein
Imagerie de la Femme·2025
Robotic nipple-sparing mastectomy with immediate prosthetic reconstruction: A prospective study about 138 consecutive procedures
Annales de Chirurgie Plastique Esthétique·2025Open Access
Therapy related myeloid neoplasm, same but different?
Bulletin du Cancer·2025
page 1 of 41Next →

Frequent Co-authors

Fabrice André(16), Étienne Brain(11), Michael Gnant(8), Giuseppe Viale(7), Martine Piccart(7), David Cameron(7), Florence Dalenc(7), Fátima Cardoso(6), Jean‐Yves Pierga(6), Carlos H. Barrios(6), Miguel Martín(6), Thomas Bachelot(6), Binghe Xu(5), Norikazu Masuda(5), Emiel J. Rutgers(5), Lajos Pusztai(5), Giuseppe Curigliano(5), Philip Poortmans(5), Meredith M. Regan(5), Jonas Bergh(5)